Clinical Trial Details

< Previous Trial     Next Trial >
Study ID STU00201148
Alan M Peaceman, MD,   Northwestern University
Title Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation
Conditions Dystocia
Interventions Drug: Oxytocin
Other: Sodium Chloride 0.9%
Phase Phase 4
Purpose Oxytocin is a medication that is often used to strengthen contractions to overcome delayed labor progress. The primary aim of this study is to determine whether receiving a higher dose of oxytocin lowers the chance of needing a cesarean section when compared to a lower dose of oxytocin. Other aims include examining the relationship between dose of oxytocin regimen and length of labor, postpartum hemorrhage, intrauterine infection, umbilical cord gas, neonatal Apgar score <5 at 5 minutes, and need for neonatal intensive care.
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Female
Accepts Healthy Volunteers:  No
Inclusion Criteria:
  • Able to give informed written consent
  • Age 18-45 years
  • Nulliparous
  • Pregnant with a singleton gestation that is equal to or greater than 36 weeks
  • Diagnosed with spontaneous labor (defined as at least 6 regular uterine contractions in an observation period of no more than 60 minutes) or spontaneous rupture of membranes. In addition, at least one of the following: cervix greater than or equal to 3 centimeters dilated or 80% effaced.
  • The participant's attending obstetric physician or midwife has determined that the participant needs administration of oxytocin infusion for labor augmentation. Labor augmentation will be defined as stimulation of uterine contractions when spontaneous contractions have failed to result in progressive cervical dilation of descent of fetus. Exclusion Criteria:
  • Women not meeting the above criteria
  • History of prior cesarean section or uterine surgery
  • Fetus in non-cephalic presentation
  • Participant is undergoing labor induction
  • Non-English speaking
  • Study Location N/A
    Contact Moeun Son, MD
    Information obtained from, on 7/1/2015. For additional information about this and other clinical trials, visit
    Please refer to this study by its identifier: NCT02487797

    Back to Search Results